Articles > Blood Cancer

  1. Precision Medicine and Immunotherapy @ ASCO16

    The American Society of Clinical Oncology (#ASCO16) annual meeting featured several significant oral scientific presentations on the blood cancers over the weekend here in Chicago. CPX-351: A session on hematological malignancies Saturday afternoon included a discussion of final data from the Phase 3 clinical trial of Celator’s drug CPX-351 (Vyxeos ®). LLS invested substantially in this study through our Therapy Acceleration Program (TAP). The study was in a small subset of elderly pati...

    Read More
  2. Putting Patients at the Center of Care at #ASCO16

    The American Society of Clinical Oncology (#ASCO16) annual meeting kicked off today as more than 30,000 researchers from around the world converged in Chicago to share their latest clinical findings on treatments and diagnostics for all cancers, and to exchange ideas about how to improve outcomes for cancer patients. Putting patients at the center of cancer care and research is this year’s theme at ASCO, something we at The Leukemia & Lymphoma Society (LLS) try to do every day. Sprin...

    Read More
  3. Significant Advance for Hodgkin Lymphoma Patients

    The Food & Drug Administration’s accelerated approval of an immunotherapy for patients with Hodgkin lymphoma who have failed other treatments is a positive development for patients who face a very poor prognosis. While Hodgkin lymphoma is now considered one of the most curable forms of cancer – with a more than 86 percent five-year-survival rate overall – those patients who relapse after treatment have a much reduced chance of survival. FDA’s approval of nivolumab (Opdivo®)...

    Read More
  4. Bringing the Patient Voice into Drug Development

    Wanting to make sure the patient voice is heard when it comes to the development of new therapies, The Leukemia & Lymphoma Society (LLS) recently brought a delegation to Washington D.C. to share personal experiences with the U.S. Food & Drug Administration (FDA). Plans for a research study to learn what patients and caregivers are looking for in new treatments were also presented. LLS’s Office of Public Policy knows the importance of pushing for new drug development, but you can...

    Read More
  5. Looking Ahead: LLS Panel Highlights Trends and Advances

    The Leukemia & Lymphoma Society recently brought together a world-renowned panel of thought leaders to discuss the latest advances and insights into blood cancer research and treatment, drug costs and patient access, and patient advocacy and policy. “There’s never a good time to get cancer but this is a phenomenal time to be fighting it,” said Louis J. DeGennaro, president and CEO of The Leukemia & Lymphoma Society (LLS).

    Read More
  6. Leading Researchers, Clinicians, Policy and Drug Development Experts, and Cancer Survivors Convene to Discuss Latest Advances and Challenges in Treating Blood Cancers

    Click here for a comprehensive media toolkit. New York – February 25, 2016 – A panel of world renowned thought leaders from research, clinical practice, policymaking, pharmaceutical industry and patient advocacy convened today to discuss and debate the latest advances and insights into blood cancer research and treatment, drug costs and patient access, and patient advocacy and policy. The roundtable was organized by The Leukemia & Lymphoma Society (LLS), the world's largest volunta...

    Read More
  7. Coming Soon: A Brave New World

    Research is inching us closer to cures for blood cancer every day – among them, therapies that unleash the immune system, reprogramming of T-cells to track down cancer cells, and personalized treatments based on a patient’s genetic make-up. Survival rates for patients with many blood cancers have doubled, tripled and even quadrupled since the early 1960s. Cures for many patients with acute lymphoblastic leukemia (ALL) and Hodgkin lymphoma have been achieved, and the five-year survival ...

    Read More
  8. Seven Insights for Better Nutrition During Cancer Treatment

    In the New Year, you may be looking to turn over a new leaf. One goal may be to improve your nutrition. Many cancer survivors struggle with food issues. In fact, research shows that up to 80 percent of people with a cancer diagnosis are expected to experience malnutrition at some point during treatment. Even before a diagnosis, as many as 40 percent of people with cancer experience unhealthy weight loss. Unhealthy weight loss can lead to decreased response to treatment, delays in treatment, a...

    Read More
  9. Renewed focus on a national initiative to cure cancer

    For more than 66 years The Leukemia & Lymphoma Society (LLS) has dedicated its energy and resources to finding cures for blood cancers, investing more than $1 billion over that time. Last night in his State of the Union address, President Obama appointed Vice President Joe Biden to take the lead in a “moon shot” mission to cure cancer. We at LLS agree the time is right. “It’s personal for everybody,” the Vice President later said in a statement. As Vice President Biden...

    Read More
  10. Huge Win for Cancer Research

    Congress has approved a $2 billion increase in funding for the National Institutes of Health. The 6.6 percent hike -- to $32.1 billion -- is the largest increase in 12 years and it will make an enormous difference in supporting cancer research in the years ahead. The bill includes a $264 million increase in funding for the National Cancer Institute (boosting NCI funding for the year to $5.2 billion – a 5.3% increase) as well as $200 million in funding for a precision medicine initiative ...

    Read More